Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 798-806

  Hu, Gang ^a,b   Li, Fu ^a   Ouyang, Kedong ^b   Xie, Fubo ^b   Tang, Xuzhen ^b   Wang, Ke ^b   Han, Sufang ^b   Jiang, Zhenzhou ^a   Zhu, Minghua ^c   Wen, Danyi ^b   Qin, Xiaoran ^b   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Shanghai ChemPartner Co Ltd   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cell; Gemcitabine; Pancreatic ductal adenocarcinoma; Resistance

Indexed keywords

CD133 ANTIGEN; GEMCITABINE;

ADOLESCENT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL STRUCTURE; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; KARYOTYPE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; SHORT TANDEM REPEAT; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KARYOTYPE; MICE; MICE, SCID; MICROSATELLITE REPEATS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863116036     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1254     Document Type: Article

References (40)

1. China Health Statistical Yearbook. Ministry of Health, China, 2010. http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010/ index2010.html
2. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994. (Pubitemid 24209062)
3. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353, 1996. (Pubitemid 26246785)
4. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
5. Ishii H, Furuse J, Nagase M and Yoshino M: Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J Gastroenterol Hepatol 20: 62-66, 2005. (Pubitemid 40143635)
6. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007. (Pubitemid 46972777)
7. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
8. Xiong HQ, Rosenberg A, Lo Buglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22: 2610-2616, 2004. (Pubitemid 41103748)
9. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212-2217, 2007.
10. El Maalouf G, Le Tourneau C, Batty GN, Faivre S and Raymond E: Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35: 167-174, 2009.
11. Mackey JR, Mani RS, Selner M, et al: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998. (Pubitemid 28450036)
12. Spratlin J, Sangha R, Glubrecht D, et al: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961, 2004. (Pubitemid 39383046)
13. Giovannetti E, Del Tacca M, Mey V, et al: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928-3935, 2006.
14. Goan YG, Zhou B, Hu E, Mi S and Yen Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207, 1999. (Pubitemid 29418726)
15. Graber HU, Friess H, Zimmermann A, et al: Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg 3: 74-81, 1999.
16. Noma B, Sasaki T, Fujimoto Y, et al: Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33: 1187-1194, 2008.
17. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W and Tonghua L: Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8: 125, 2009.
18. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007. (Pubitemid 47355323)
19. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
20. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007. (Pubitemid 350160137)
21. Du Z, Qin R, Wei C, et al: Pancreatic cancer cells resistant to chemoradiotherapy rich in 'stem-cell-like' tumor cells. Dig Dis Sci 56: 741-750, 2011.
22. Yauch RL, Gould SE, Scales SJ, et al: A paracrine requirement for hedgehog signalling in cancer. Nature 455: 406-410, 2008.
23. Tian H, Callahan CA, DuPree KJ, et al: Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA 106: 4254-4259, 2009.
24. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461, 2009.
25. Levan A, Fredga K and Sandberg AA: Nomenclature for centromeric position on chromosomes. Hereditas 52: 201-220, 1964.
26. Weiss MC and Green H: Human-mouse hybrid cell lines containing partial complements of human chromosomes and functioning human genes. Proc Natl Acad Sci USA 58: 1104-1111, 1967.
27. Masters JR, Thomson JA, Daly-Burns B, et al: Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98: 8012-8017, 2001. (Pubitemid 32642678)
28. Cabrera CM, Cobo F, Nieto A, et al: Identity tests: determination of cell line cross-contamination. Cytotechnology 51: 45-50, 2006. (Pubitemid 44763385)
29. Takano S, Togawa A, Yoshitomi H, et al: Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 15: 3157-3168, 2008.
30. Giovannetti E, Mey V, Danesi R, Mosca I and Del Tacca M: Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10: 2936-2943, 2004. (Pubitemid 38619668)
31. Dembinski JL and Krauss S: Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 26: 611-623, 2009.
32. Dangles-Marie V, Pocard M, Richon S, et al: Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 67: 398-407, 2007. (Pubitemid 46142799)
33. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O and Jalanko H: Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53: 197-202, 1986. (Pubitemid 16095559)
34. Iwamura T, Taniguchi S, Kitamura N, et al: Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). J Gastroenterol Hepatol 7: 512-519, 1992.
35. Lundin J, Roberts PJ, Kuusela P and Haglund C: The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 69: 515-519, 1994. (Pubitemid 24076471)
36. Arumugam T, Ramachandran V, Fournier KF, et al: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828, 2009.
37. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005. (Pubitemid 40488633)
38. Clarke MF, Dick JE, Dirks PB, et al: Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006. (Pubitemid 44623625)
39. Lee CJ, Dosch J and Simeone DM: Pancreatic cancer stem cells. J Clin Oncol 26: 2806-2812, 2008.
40. Jimeno A, Feldmann G, Suárez-Gauthier A, et al: A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314, 2009.